Aurinia Pharmaceuticals Inc. provided earning guidance for 2022. For fiscal year 2022, the Company maintains its net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150 to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.225 USD | -1.23% | -6.06% | -42.21% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.21% | 755M | |
+8.90% | 115B | |
+9.69% | 105B | |
-12.84% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.92% | 16.52B | |
-16.28% | 16.01B | |
+1.42% | 14.14B | |
+17.62% | 10.71B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Earning Guidance for 2022